Table 1 Patients baseline demographics and disease characteristics
Characteristic | Selinexor 60 mg QW/BIW + carboplatin 6 AUC Q3W (N = 6) | Selinexor 60 mg QW/BIW + doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 Q3W (N = 4) | Selinexor 40 mg QW + FOLFIRIa (N = 3) | Selinexor 60 mg QW + irinotecan 125 mg/m2 D1 and 8 Q3W (N = 3) | Selinexor 40 mg QW + XELOXb (N = 3) | All patients (N = 19) |
|---|---|---|---|---|---|---|
Age at consent (years) | ||||||
Median range | 56.1 (31.2–76.1) | 61.7 (23.6–64.9) | 49.9 (38.1–70.7) | 67.8 (57.9–72.3) | 65.9 (51.8–72.8) | 60.6 (23.6–76.1) |
Gender, N (%) | ||||||
Male | 1 (17) | 2 (50) | 1 (33) | 1 (33) | 2 (67) | 7 (37) |
Female | 5 (83) | 2 (50) | 2 (67) | 2 (67) | 1 (33) | 12 (63) |
Race/ethnicity, N (%) | ||||||
White | 4 (67) | 4 (100) | 3 (100) | 1 (33) | 3 (100) | 15 (79) |
Hispanic | 0 | 0 | 0 | 0 | 0 | 0 |
Black | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
Asian | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
ECOG performance status, N (%) | ||||||
0 | 1 (17) | 0 | 1 (33) | 2 (67) | 1 (33) | 5 (26) |
1 | 5 (83) | 4 (100) | 2 (67) | 1 (33) | 2 (67) | 14 (74) |
Primary tumor, N (%) | ||||||
Ovarian | 0 | 2 (50) | 0 | 0 | 0 | 2 (11) |
Breast | 3 (50) | 0 | 0 | 0 | 0 | 3 (16) |
Colorectal cancer | 0 | 0 | 1 (33) | 1 (33) | 1 (33) | 3 (16) |
Endometrial/fallopian | 0 | 0 | 0 | 0 | 0 | 0 |
Lung | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
Neuroendocrine | 0 | 0 | 1 (33) | 1 (33) | 0 | 2 (11) |
Pancreas | 0 | 0 | 1 (33) | 0 | 1 (33) | 2 (11) |
Esophageal | 0 | 0 | 0 | 0 | 0 | 0 |
Head and neck/salivary gland | 1 (17) | 0 | 0 | 1 (33) | 0 | 2 (11) |
Liver/cholangiocarcinoma | 0 | 0 | 0 | 0 | 1 (33) | 1 (5) |
Sarcoma | 0 | 1 (25) | 0 | 0 | 0 | 1 (5) |
Prostate | 0 | 1 (25) | 0 | 0 | 0 | 1 (5) |
Others | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
Prior lines of systemic therapies, N (%) | ||||||
0–1 | 1 (17) | 0 | 0 | 0 | 0 | 1 (5) |
2–3 | 4 (67) | 3 (75) | 2 (67) | 2 (67) | 2 (67) | 13 (68) |
4–5 | 1 (17) | 1 (25) | 1 (33) | 0 | 1 (33) | 4 (21) |
> 5 | 0 | 0 | 0 | 1 (33) | 0 | 1 (5) |
Median range | 2.5 (1.0–4.0) | 2.0 (2.0–4.0) | 3.0 (3.0–5.0) | 3.0 (2.0–6.0) | 3.0 (2.0–4.0) | 3.0 (1.0–6.0) |